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Abstract
Background: Depression is a common disorder with a lifetime prevalence of 16 %. Despite the availability of
several treatment options for depression, many patients do not respond to treatment and develop chronic illness
associated with several secondary comorbidities. Behavioural activation (BA) is a simple therapy that has the
potential for improving symptoms of depression and quality of life in patients with depression. The effectiveness of
BA has not, however, been tested in a group format for patients with moderate to severe depression attending a
specialized mood disorders tertiary care setting. Group format has the advantage of treating more patients at the
same time especially in resource-limited settings. The primary objective of this pilot study is to test the feasibility of
a main trial by assessing the recruitment and retention rates, average group size, completion of data and resources
needed and receive the participants’ feedback on the intervention. The secondary objective is to explore the
change in mood and quality of life measures in adults with depression receiving BA.
Methods/Design: Using a pragmatic pilot randomized controlled trial design, we will test the feasibility of a large
trial to assess the effectiveness of BA added to usual care compared to a depression support group with usual care.
Participants will be randomized after obtaining informed written consent to one of two study arms. Face-to-face
group therapy will be provided in a hospital setting by trained therapists. Intervention and control groups will be
seen twice weekly for 10 weeks and then once weekly for further 8 weeks. Participants will be completing mood
symptom scales, quality of life questionnaires and anthropometric measures and provide blood samples for future
analysis of biomarkers of response to treatment. During the pilot study we will also solicit participants’ feedback
and experience regarding the number, frequency and contents of the sessions as well as to explore participant
perceptions of barriers or benefits associated with the BA program.
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Discussion: The pilot study will help to inform a larger trial and assist in modifying the intervention based on
patients’ feedback.
Trial registration: Clinicaltrials.gov Identifier NCT02045771.
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Background
Depression is a common disabling disorder affecting 11.2
to 16.0 % of the general population [1, 2], and it is as-
sociated with a high risk of permanent disability (HR
1.48, 95 % CI 1.30, 1.69) and mortality (HR 2.50, 95 %
CI 1.80, 3.48) [3].
Depression is a complex and potentially chronic disorder
that requires several treatment interventions to achieve re-
mission. Antidepressant medications have shown to be ef-
ficacious for some patients, but many patients develop
troublesome side effects, and 42.7 % of patients show inad-
equate response to treatment [4, 5]. Studies have also
shown that a large proportion of patients with depression
(55.3 %) continue to have ongoing depressive symptoms at
follow-up [6]. In addition, many patients prefer non-
pharmacological interventions or report troublesome side
effects. Therefore, investigating other treatment modalities
is of critical value to the management of depression. Sev-
eral psychotherapies have been shown to be effective in
the management of depression alone or in combination
with pharmacotherapy [7]. Cognitive behavioural therapy
(CBT) [8] and behavioural activation (BA) [9] are consid-
ered as effective treatments for depression [10–12]; how-
ever, the evidence for BA therapy especially in a group
format is less well-investigated compared to CBT. Al-
though CBT is a commonly used treatment option for pa-
tients with depression, it may not be suitable for many
patients as it requires a level of psychological insight in
order to delve into complex understandings of core beliefs
and behaviours. Additionally, an acceptance of psycho-
logical therapy and the motivation to change are also ne-
cessary for CBT treatment [13].
Group therapy has the advantage of delivering treat-
ment to a larger number of patients within the same
time that it takes to provide individual therapy with
comparable benefits for many behavioural and cognitive
forms of therapy [14]. Therefore, group therapy can be
cost effective, reducing wait time and reaching a larger
number of patients. In addition to the limited research
on BA group therapy and depression, there is also a lack
of research on the effectiveness of BA in improving qual-
ity of life, commonly affected in depression, in individ-
uals with major depressive disorders [15].
The proposed behavioural activation program, Out of
the Blues, will be tested for feasibility using a pilot study
through a mixed method study including a pilot prag-
matic randomized trial and a qualitative study compo-
nent. The pilot trial will inform the design of a main
trial. Pilot trials provide investigators the opportunity to
assess feasibility, acceptability and cost of interventions
intended to be tested on a large scale [16]. Pilot trials
are not intended for testing intervention effectiveness
but instead for evaluating important trial processes such
as recruitment rate, attrition rate, potential for collabor-
ation among international settings, as well as the accept-
ability of the intervention itself [16]. Important aspects
of the intervention such as the use of interview rooms
and practicality of using mobile computers to upload
activity-tracking data require assessment prior to use in
the full trial. Providing investigators an opportunity for
process evaluation prior to trial initiation allows for the
modification of critical flaws to the study design before
these problems impact major study findings [16].
Behavioural activation program summary: “Out of the
Blues”
The Out of the Blues program’s primary goal is to reduce
depressive symptoms and reintegrate patients more fully
into their personal and professional lives thus improving
quality of life and facilitating the attainment and main-
tenance of remission from depression. The Out of the
Blues program includes several components to support
individuals with depression reintegration to former ac-
tivities as well as the acquisition of new skills in order to
reduce the symptoms of depression, improve quality of
life and achieve prolonged remission. The program com-
ponents are centred on behavioural activation (BA) [9]
with complementary interventions including recreation
activities and behavioural modifications based on the
principle that what you do affects how you feel. The
complementary components aim to improve physical ac-
tivity and promote a healthy lifestyle. They include skill
building related to coping with stress and problem solv-
ing intended to improve overall health and wellbeing
[17]. The Out of the Blues program begins with the be-
havioural monitoring of daily activities (using the daily
activity record) by examining the participant’s activity
and engagement levels with different aspects such as
home, work, leisure and social activities. This will be
followed by group therapy focused on encouraging
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participants to engage in activities that are identified by
the participants through the activity record as personally
important to them. As participants progress in the pro-
gram, they will continue to monitor their activities, de-
pressive symptoms and quality of life. Improvement in
mood and quality of life at the end of the program will
be measured using standardized instruments that are de-
scribed in detail later in the protocol.
The Out of the Blues program will use a structured
approach, including weekly face-to-face sessions, home-
work that includes recording activities (individualized
activities that align with the participants’s values), rebuild-
ing of individual skills or learning new skills in order to
improve depressive symptoms and the quality of life of
participants. If shown to be effective, the Out of the Blues
program will be made available to all patients with depres-
sion attending the Mood Disorders Program, a tertiary
care hospital-based centre. A multidisciplinary team of cli-
nicians that includes psychiatrists, occupational therapists,
recreational therapists and clinical psychologists designed
this program. This program is intended to be adminis-
tered by clinicians with training in any of these designa-
tions; however, the inclusion of an integrated team is
preferable. Ultimately the goals of the program are to:
1. Reduce depressive symptoms to achieve remission of
depressive disorders
2. Enhance patients’ strengths and skills to fulfil their
goals in life as demonstrated by return to/or starting
new work (at home activities or work place),
education or volunteering for activities
3. Improve physical health by reducing unhealthy
behaviours (example sedentary lifestyle)
4. Encourage social network building and community
activities
5. Enhance the likelihood of prolonged remission by
achieving the above goals
However, before embarking on the full program, a
pilot study to assess the feasibility of delivering this new
program for patients with depression at a tertiary hospital-
based centre is needed. In this study protocol, we present
the details of the planned pilot study.
The choice of comparators for the pilot trial
The intervention (Out of the Blues), why behavioural
activation?
Definition of behavioural activation Originally a com-
ponent of cognitive therapy, behavioural activation is the
use of strategies such as activity scheduling, mastery/
pleasure ratings and graded task assignments to change
one’s perception of specific situations [9]. It involves the
use of activities to improve life situations and depressed
mood [9].
BA individual therapy has been shown to be effective
in the treatment of depression compared to cognitive
therapy, antidepressant and a placebo [9, 18–20]. BA
was also found to be a flexible treatment that can be in-
dividualized to each patient [9]. A meta-analysis of 16
studies which included 780 participants (241 participants
were in the BA intervention) [21] found a significant
positive effect of activity scheduling, a component of be-
havioural activation, on reducing depressive symptoms
with a relatively large effect size (0.87, 95 % CI 0.6, 1.15).
This effect size is comparable to treatment effects seen
in other treatment modalities for depression including
antidepressant medications [22, 23]. This meta-analysis
combined studies of BA provided in group (n = 4) or in-
dividual format (n = 12) of varying numbers of session
from as low as 4 to as high as 20 sessions [21] and in-
cluded only one component of BA (activity scheduling).
The number of studies using BA in a group format is
limited to a small number of participants and short
follow-up duration. In addition, the majority of patients
included in these studies suffered from mild to moderate
depressive symptoms in community-based treatment
settings. We will test the effectiveness of BA in a repre-
sentative sample of patients with depression attending a
tertiary care hospital setting using a pragmatic study de-
sign. The BA intervention will be delivered in a group of
6–12 participants as an adjunct therapy to usual care.
Usual care is currently received at the Mood Disorders
Program and includes pharmacotherapy, psychotherapy,
occupational therapy, case management and regular
follow-up visits to the clinic. No structured BA interven-
tion is currently offered at this tertiary mood disorders
clinic. While we acknowledge that studies often provide
“standard of care,” as the comparator arm, we are reluc-
tant to use this term when defining our own compara-
tor. Contention exists in the medical community over
use of the term “standard of care”, which stems largely
from the lack of consensus as to (1) what constitutes ap-
propriate use of the term, (2) what expertise is required
to declare an intervention to the standard of care, and
(3) what level of evidence is adequate to support or re-
fute a therapy as the standard [24]. In fact, researchers
suggest that the term not be adopted for any interven-
tion unless confirmatory randomized controlled trials or
meta-analyses exist to support this declaration [24]. Rec-
ognizing that there is limited evidence to suggest that
what is provided to patients in our comparator arm ful-
fils the criteria for “standard of care,” we have elected to
use the term “usual care” to describe the intervention
provided for the comparator arm of this trial.
The development of this intervention along with its
acceptability among patients with major depressive dis-
order has been assessed by our team and thoroughly de-
scribed elsewhere; this work is currently under review [25].
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The control (The Blues Breakers)
In addition to usual care, the control group will be of-
fered a support group therapy format delivered at the
same place, same visit frequency and same duration of
program as the intervention group. This support group
will be unstructured with no therapist involvement. Par-
ticipants will be given the group meeting dates and time.
Following this, a nurse with specialized training in re-
search (education in data collection) who is not trained
in behavioural activation will be present at the group
time to collect study-related instruments and check the
suicide risk question on the mood scales to ensure par-
ticipant safety and clinical care. The participants will be
asked to choose a topic of discussion, and one participant
will lead the discussion. The choice of topic is entirely up
to the participants.
We acknowledge that using an active control group
has implications for the results of this work. The control
group is receiving an enriched “usualcare” whereby pa-
tients enter an adjunct support group. Support groups
are demonstrated as effective for improving quality of
life [26], and thus, the implications of an active control
arm will require consideration in the discussion and in-
terpretation of findings for this pilot trial. This support
group is intended to simulate the intervention group for-
mat to minimize risk of a biased estimate of BA effect-
iveness by reducing the potential placebo effect [27]
which may result from frequent clinic visits and having
additional attention beyond usual care.
Study question and hypothesis of the main study
In patients with depressive disorder attending a special-
ized hospital-based mood disorders clinic, does the
addition of a behavioural activation program delivered in
a group format decrease depressive symptoms and im-
prove quality of life compared to treatment as usual and
a support group after 18 weeks of treatment?
We hypothesize that group behavioural activation is
an effective treatment for depressive disorder in patients
with depression.
Study objectives
Pilot study primary objectives
The main goal of the feasibility and pilot phase is to en-
hance the success of the full trial by testing the feasibility
of conducting a randomized controlled trial to assess the
effectiveness of a behavioural activation program for de-
pression delivered through a group-based, face-to-face
intervention in addition to care as usual to reduce de-
pressive symptoms and improve quality of life. In
addition, by using a qualitative study component, this
study will also assess engagement in treatment among
patients with depressive disorders and modify the proto-
col for the main trial based on the feedback received by
the participants in the pilot phase. Engagement will be
evaluated during the qualitative stage using open-ended
questions aimed at determining patient satisfaction with
the current treatment design. Engagement will also be
evaluated during the BA program using assessment of
attendance and involvement in group. In addition, the
qualitative study aspect aims to collect data relating to
participants’ experience in the program, as well as their
perceptions of improvements in mood and functioning.
This qualitative data will provide feedback to shape the
main trial protocol.
The pilot primary objectives are therefore summarized
after Thabane and colleagues [16]:
1. Assess the feasibility of the study process in
terms of recruitment, retention, number of
sessions completed, average group size and data
completion
2. Assess resources needed including the use of
interview rooms, group room, mobile computers to
upload activity-tracking data, communication with
participants’ clinicians and time investment in the
program by the study clinicians.
3. The objective of the qualitative component of the
pilot study is to ensure that the treatment program
is patient-centred by modifying the protocol for the
main trial as suggested by participants. More
specifically, the qualitative study objectives are:
(a)Solicit patient and clinician feedback on the
behavioural activation program so that the
program can be modified to meet the needs
and preferences of the patient participants.
Data collected towards this objective will help
inform future programs and future research on
this particular program of behavioural
activation.
(b)Throughout the study period, collect information
from participants in the intervention and control
arms of the study about their perceptions of their
depression and quality of life in general.
Collecting this information throughout the study
from both sets of participants will allow us to
compare and contrast the patients’ individual
perspectives of the changes that they are
experiencing. We will be able to compare this
analysis with the quality of life measures to
determine if there are additional domains of the
illness experience affected by the behavioural
activation program that are not covered by
existing measures. These interviews throughout
the study period also provide an opportunity to
establish whether patients feel that their needs
are being met, and whether they feel the program
is responsive of such needs.
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Pilot study secondary objectives
1. Assess the change in mood using the Beck
Depression Inventory between and within the
intervention and control groups
2. Explore the change in quality of life scores between
and within the intervention and control groups
Trial Methods/design
This pilot study is a mixed-methods design including an
open label pragmatic randomized trial and a qualitative
study of participants’ experiences. The quantitative com-
ponent of the study includes gathering data on demo-
graphics, recruitment rate, data completion, retention in
pilot trial and changes in mood and quality of life mea-
sures. The qualitative component will be used to gather
participants’ experiences, beliefs and opinions about two
topics: (1) the experience of participating in the behav-
ioural activation program or the support group (control
condition) and (2) their evolving perceptions of their in-
dividual depressive illness and quality of life. Based on
the analysis of qualitative data pertaining to the first
topic, the behavioural activation program may be modi-
fied for the main trial. The qualitative study will involve
multiple interviews and focus groups which will take
place before, during and after the pilot intervention
period. Participants will be drawn from both the inter-
vention and control arms of the pragmatic randomized
controlled trial. More details about the qualitative study
can be found below.
The pilot pragmatic randomized controlled trial study
design is a parallel 1:1 allocation comparing behavioural
activation plus usual care to support group plus usual
care. For this pilotstudy we will adopt the following princi-
pals simulating naturalistic real-life clinical setting to test
the study question based on the pragmatic design [28, 29]:
1. No restrictive inclusion criteria will be used. Adults
with major depressive disorder will be asked to
participate in this study
2. Clinicians will deliver the BA program to
participants randomized to receive the intervention
3. The intervention will be an add-on to usual care
4. The comparison group will receive usual care that
may include medications, CBT and other therapies
as required and decided by their clinical care
5. The primary outcome is patient-important
(improvement in depressive symptoms and quality
of life)
6. There will be no measures to improve adherence to
the study intervention or the comparator.
Trial design characteristics
We assessed the characteristics of the proposed trial
using the pragmatic-explanatory continuum indicator
summary (PRECIS) [30] on sample size, and outcome
measures, eligibility criteria, flexibility of intervention
administration, degree of practitioner experience needed
for those applying the intervention and flexibility of ad-
ministration of the comparator intervention from in-
cluded trials. PRECIS is an accepted tool for assessing
the design of trials on a continuum of effectiveness ver-
sus efficacy. Using the PRECIS criteria [30], Fig. 1 shows
the current trial design based on the eight criteria
“spokes” adapted from (http://www.support-collaboration.
org/precis.pdf).
Study setting
The study setting is an outpatient specialized mood dis-
orders clinic at the Mood Disorders Program, St.
Joseph’s Healthcare Hamilton. This is a single site study;
however, the patients attending the mood disorders
clinic are likely to represent the most severe end of the
spectrum as this clinic acts as a tertiary care centre re-
ceiving referral from the Greater Hamilton and sur-
rounding areas for consultation and management of
patients with inadequate response to treatment.
Clinicians providing BA (Out of the Blues group)
All clinicians (KM, KL and JW) involved in the interven-
tion and administration of the study BA program work
at the Mood Disorders Program and are trained in the
use of BA for treatment of depression. All clinicians
completed a workshop on BA in April 2013 and read
three BA workbooks as training manuals (Michael Addis
and Christopher Martell. Overcoming Depression One
Step At A time, the new behavioural activation approach
to getting your life back 2004; Jonathan Kanter, Andrew
Busch and Laura Rusch. Behavioural Activation 2009;
and Christopher Martell, Sona Dimidjian and Ruth
Herman-Dunn. Behavioural Activation for Depression, a
clinician guide 2010).
Clinicians supervising control group (The Blues Breakers
group)
Clinicians working at the Mood Disorders Program who
provide usual care to patients attending the clinic will
supervise the control group sessions. Clinicians running the
control group have no training in behavioural activation.
All study participants (intervention and control groups)
will continue to receive treatment as usual during their
study participation. Information on the treatment received
as part of usual care will be collected.
Eligibility criteria
Adult patients (18 years or older) with major depressive
disorders will be asked to participate in this study.
Patients referred to the Mood Disorders Program and
receiving treatment for depression as per usual clinical
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care including antidepressants medications, individual
psychotherapy, cognitive behaviour therapy and other
treatment modalities are eligible to participate in this
study. All participants must be able to provide written
informed consent and can attend the program sessions
at the Mood Disorders Program. We will exclude
patients who are unable to understand written and
spoken English (the intervention is based on a group
with English-speaking therapists and manuals) and who
have a primary diagnosis other than depression. We
acknowledge that placing a language restriction on the
eligibility criteria may impact the generalizability of find-
ings from this trial. However, while Hamilton may be
pragmatically multilingual by nature, the delivery of
services in this area (as well as the majority of Canada
notwithstanding Quebec and New Brunswick) is deliv-
ered in English or with the use of a translator. In this
study, we aimed to demonstrate changes in symptoms of
depression and quality of life measures under optimal
conditions; however, we may consider evaluating its
effectiveness via translator at a later stage.
The intervention
Figure 2 describes the components of the intervention
(adapted from Perera et al. [31]), number of sessions and
time line of the pilot study. A specific intervention man-
ual including detailed session-by-session administration
of BA and complementary measures has been designed
based on clinicians’ training, existing literature and BA
manuals; the Out of the Blues intervention manual is
available from authors upon request. In addition, the
questionnaires and study instruments selected for the pilot
trial are presented in Table 1. These instruments are as
recommended by the BA manuals and previous literature




1. Assess the feasibility of the study process in terms of
recruitment, retention, number of sessions
completed, average group size and data completion.
2. To assess resources needed including the use of
interview rooms, group room, mobile computers to
upload activity-tracking data, communication with
participants’ clinicians and time investment in the
program by the study clinicians.
3. The qualitative component of the pilot study is to
assess the need to modify the protocol for the main
trial based on the participants’ feedback thus aiming
to provide a patient-centred treatment program.
Secondary:
1. Assess the change in mood using the Beck
Depression Inventory between and within the
intervention and control groups.
Fig. 1 BRAVE pilot pragmatic trial design. The PrECIs tool shows the current pilot study design to be closer to a pragmatic than explanatory trial
(http://www.cmaj.ca/content/180/10/E47.full). The red line represents the score for each domain “spoke” of the proposed BRAVE trial
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Fig. 2 (See legend on next page.)
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2. Explore the change in quality of life scores between
and within the intervention and control groups.
Timeline
The pilot study will be conducted over 18 weeks with a
total of 30 visits including 28 sessions of behavioural ac-
tivation in the intervention group and 28 sessions of
support group in the control group. Both groups will
also receive usual care. The study timeline is presented
in more detail as in Fig. 2.
Sample size
For the feasibility and pilot trial, we will recruit 10 par-
ticipants in each arm. This number is based on the
recommended group therapy size of 6–12 per group ses-
sion. The pilot data will help to modify the sample size
calculation for the main trial.
Recruitment
Patients with a diagnosis of depressive disorders referred
to the mood disorders clinic will be approached for par-
ticipation in the study. Consecutive patients attending
the clinic will be asked if they are interested in partici-
pating in the study. Following initial screening for eligi-
bility, patients will be asked to provide written informed
consent prior to any study-related procedures. Potential
participants will be approached through clinicians with
direct clinical contact with potential participants. A
Table 1 Pilot study instruments









60 Baseline ✓ ✓
PAR-Q Assess readiness for physical activity Self 10 Baseline ✓
Assumption of
risk form
Inform about risks of attending program Self 5 Baseline ✓
BDI-II Monitor depressive symptoms Self 5 Baseline ✓ ✓
Weekly ✓ ✓
End of study ✓ ✓
SF12, WSAS,
Q-LES-Q-SF
Quality of life Self 10 Baseline ✓ ✓
Session 10 ✓ ✓
End of study ✓ ✓
BADS Measure activation and avoidance behaviours Self 5–10 Baseline ✓ ✓
Weekly ✓
End of study ✓ ✓




15–30 Baseline ✓ ✓
Session 10 ✓
End of study ✓ ✓
EQ-5D-5 L Health-related quality of life to generate health
utility index for calculation of quality-adjusted life
years for economic evaluation
Self 5 Baseline ✓ ✓
End of study ✓ ✓
Activity-tracking
form
To track activity Clinician and patient 5 Weekly ✓
(See figure on previous page.)
Fig. 2 Pilot study components. a-eligibility and consent, b-baseline interview, diagnosis and demographics, c-physical measurements (height,
weight, body fat percent), d-blood draw, e-Beck Depression Inventory (BDI II), f-Behavioural Activation for Depression Scale (BADS), g-Quality of life
scales (SF-12, WSAS, and Q-LES-Q-SF), h-Leisure Motivation Scale (LMS), i-assumptions of risks, j-Physical Activity Readiness Questionnaire
(PAR-Q), k- Activity tracking form, l- EQ-5D-5L a standardized instrument to measure health outcomes, m-qualitative individual interviews, n-focus
group. S1-behavioural activation for depression, S2-values assessment, S3-goal setting, S4-Breaking it down, S5-avoidance and depression,
S6- rumination, S7-ruminations II, S8-relationships, S9-involving others and social skills, S10-asseriveness and communication skills, S11-assetiveness
and relaxation strategies, S12-leisure education, S13-problem solving, S14-team building and cooperative games, S15-nutrition and laughter yoga,
S16- mindfullness and planning of group outing, S17-understanding sleep, S18-group outing, S19-getting back to work and volunteering, S20-S23
and S25-27 relapse prevention and troubleshooting, S24-booster group/adventure based day trip, S28-booster session and end of study. The
qualitative components (l and m) are delivered in the pilot phase only. Adapted from Perera et al. [31]
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simple log will be kept to track the number of individ-
uals approached, number declined, and number ex-
cluded and reasons for exclusion.
Allocation and randomization
We will employ a parallel group design to test the feasi-
bility of behavioural activation study in depression. Eli-
gible and consenting patients will be randomly allocated
to the intervention or control arms using a 1:1 allocation
ratio. Allocations will be randomly assigned using a
block randomization system of block sizes of 2, 4 and 6.
Blinding and concealment of randomization
This pilot trial is an open label trial as blinding is not
possible for participants (behavioural activation inter-
vention) or the clinician administering the intervention.
However, a research assistant not involved in the inter-
vention or the control condition will allocate the partici-
pants based on the randomization system provided. The
clinicians referring participants, the participants at the
time of enrolment (signed consent and baseline visit
completed) and the clinicians providing the BA interven-
tion or the control groups will have no knowledge of the
allocation prior to the start of the first intervention or
control groups. Following the consent and baseline as-
sessment, participants will be informed what group they
will be attending. The clinicians will receive a list of the
participants to attend their respective groups. Allocation
concealment will be ensured by assigning study ID num-
bers to all participants at the time of enrolment and be-
fore randomization. The allocation then occurs as above
using the assigned ID numbers with no other identifiers;
these IDs will then be placed in an opaque envelope and
randomly picked from the envelope and allocated to the
intervention or control based on the block randomization
system. Following the completion of the random alloca-
tion process, the ID numbers will then be identified by
name, and the participants will be informed of their
assigned groups. Further allocation concealment will
occur at the data analysis level where data analyst will be
blinded to the allocation. The clinical outcomes measures
are self-administered, and therefore, the participants can-
not be blinded to their allocation group.
Data collection methods
Full description of the study instruments and timeline of
administration are given in Table 1. A specifically de-
signed case report form (CRF) will be used to collect the
data using paper forms. A defining characteristic of
pragmatic trials includes the use of simple easy-to-
administer case report forms and psychometric tools. To
ensure the feasibility of our baseline assessment instru-
ments, we have elected to include as few psychometric
tools as possible. For instance, we are only using a single
depression scale and quality of life measure. The BDI-II
includes 21 items measured on a scale of 0–3, with
higher scores indicating a higher depressive symptom se-
verity [32]. The BDI-II score is analyzed using four cat-
egories of depressive symptom severity [32]. We have
chosen the BDI-II for two purposes. Firstly, the BDI-II
will measure depression severity among participants
[33]. The BDI-II identifies prognostically relevant depres-
sive symptoms, such that it strongly predicts a variety of
patient-important outcomes for populations suffering with
depressive disorders [34]. Patient-important outcomes
correspond to meaningful endpoints which identify closely
with the patients values and preferences within this popu-
lation, which may include physical or emotional symp-
toms, quality of life or social factors such as ability to
obtain employments. Secondly, the BDI-II was chosen as
a safety measure for the trial which is described later in
the data-monitoring section of the trial protocol.
Qualitative data collection
Using the methodology of Grounded Theory [35, 36],
we will engage in an iterative data collection and ana-
lysis process to address our two qualitative research
objectives.
Research objective (a) will be pursued by collecting
focus group data from patient participants in the inter-
vention and control arms and from clinicians involved in
those patients’ care.
We have chosen to use focus groups for this objective
to enable participants to build off of each other’s ideas
and respond to the feedback shared by the other partici-
pants. These focus groups ask participants to comment
on their shared experiences as a group, and therefore,
the focus group is an appropriate method of data collec-
tion [37, 38]. Additionally, since the intervention being
studied is a group-based program that aims to increase
interaction and communication skills of patient partici-
pants, a focus group setting will be familiar to the pa-
tient groups. We will conduct homogeneous focus
groups composed of either 4–7 patients or 4–7 clini-
cians at 3 time points: during weeks 3, 6, and 18 of the
program. All program participants and their clinicians
will be invited to participate, and anyone who is willing
will be able to participate in a focus group. Focus groups
will be conducted by a trained qualitative researcher
who is not a clinician involved with patient care. Focus
groups will be audio-recorded, and those recordings will
be professionally transcribed for analysis [39]. A second
researcher will take field notes during the focus group,
noting body language, group dynamics and other aspects
which are not recorded on the audiotape [37]. We will
not be collecting this information (body language) for
later use in a discourse analysis. Since we are administer-
ing a new intervention, it is important that we record all
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aspects of face-to-face contact, including during the
qualitative sessions. The question guide for the focus
groups will evolve throughout the process to reflect the
emerging theory but will focus on the participant’s ex-
perience of the program and actively solicit constructive
feedback to improve the intervention and ensure that it
is as acceptable as possible to both patients and clini-
cians [35, 40]. For example, we might ask patients if the
number of visits per week is manageable, if the timing of
the program is acceptable, what barriers they experience
to attending, what activities they find are particularly
helpful or unhelpful etc. The focus group and interview
guides are available from authors upon request. We
might ask clinicians about their perceived need for this
type of program for their patients, their willingness to
refer patients to the program and whether they have ob-
served a change in their patient since beginning the
program.
Research objective (b) will be accomplished through
individual interviews with patients (all patients will be
invited to participation in these interviews) from both
the control and intervention arms of the randomized
study. Each patient will be interviewed twice, during
weeks 2 and 10 of the program. Individual interviews
were chosen to allow the participant the confidentiality
to speak frankly about personal and sensitive issues. Par-
ticipants will be asked about their perceptions of their
depression and how it affects their quality of life, in
whatever way they define quality of life. Participants will
be asked whether they feel the program is tailored to-
wards their needs and what changes should be made to
address such needs. Answers to these questions will
allow us to ensure that the program is patient-centred.
Congruent with Grounded Theory, we will use purposive
and theoretical sampling, and data collection will con-
clude when theoretical saturation is reached [35]. Theor-
etical saturation means that additional data collection
does not yield new ideas or themes [35]. The individual
interviews will be audio-recorded and professionally
transcribed [39].
Data management
Data from CRFs will be entered into research Electronic
Data Capture (REDCap) (http://project-redcap.org/).
Paper copies of the data will be stored securely as source
documents, and electronic data will be hosted in the
local institution server with passcode protection and
electronic security measures in keeping with institutional
policy and privacy regulations. Reports will be generated
weekly to check data quality and missingness, whereby
we will determine which variables are not being col-
lected or captured properly.
Statistical analyses
Data generated from the pilot study will help inform the
main trial by testing the study procedures. Therefore, no
formal statistical analyses will be performed for the pilot
data. Description of the study participants and simple
tabulation of the pilot data will be presented. Data
exploration will be performed to compare the mean dif-
ference (and 95 % confidence intervals) of the BDI-II
and quality of life scores between intervention and com-
parator groups at the end of the trial using t test and
within groups for repeated measures using analysis of
variance (ANOVA). All randomized participants will be
included in the analyses. The statistical analyses of the
pilot data will be exploratory only as the sample size will
not allow for definitive analyses. We will use Stata ver-
sion 12 software for analyses.
Summary of the study objectives and proposed statis-
tical analyses are presented in Table 2. We will consider
the following criteria to deem the study is feasible to be
conducted:
1. At least 20 % of potential participants agree and
enrol in the study (given the time commitment of
Table 2 Summary of the study objectives, outcomes and analysis plans
Aim Objectives Outcome Hypothesis Statistical analysis
Primary Assess feasibility of
recruitment, retention,
group size and data
completion
Recruitment and retention rates, data
missingness
BA is feasible and
acceptable
Descriptive statistics: mean and SD
for continuous variables and
proportions for dichotomous
variables
Assess resources needed Group and interview rooms needed, number
of clinicians to deliver groups, average length
of group session (time needed per session)
Descriptive statistics: mean and SD





Qualitative study feedback Qualitative study results based on
grounded theory
Secondary Clinical outcomes: BDI-II
and quality of life




Between and within group
comparisons of the BDI-II and
quality of life scales
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18 weeks and frequency of face-to-face visits we
would expect fewer participants to enrol)
2. Completion rate of 80 %, that is to say, we will have
final visit data on at least 80 % of the participants
3. We expect 80 % completion of weekly measurement
scales
Qualitative data analysis
The focus group sessions will be recorded using three
devices in efforts to ensure that data are properly cap-
tured and to avoid any recording malfunction. Conver-
sations will be transcribed in real-time by co-facilitators,
and audio recordings will be used to verify these tran-
scriptions. Facilitators will take extensive field notes,
track participant responses, and ensured data are ad-
equately collected from research participants.
We will use the analytical techniques of grounded
theory, including line-by-line coding, thematic coding
and constant comparative analysis [35, 41, 42]. These
techniques require the analyst to look at small pieces of
the data and then group and re-group the data into dif-
ferent categories. Additional data requires the entire
dataset to be re-read and re-analyzed, to ensure the cat-
egories are still comprehensive and relevant. Data ana-
lysis will begin as soon as the first data are collected,
and emerging findings will inform future data collec-
tion [35]. Three members of the research team indi-
vidually reviewed the transcripts of the focus group to
inductively identify themes before further analysis of
the data. After further coding of the identified themes,
they created an inclusive master list of themes. Dissent-
ing opinions will be discussed and resolved. NVivo 9
software will be used to facilitate data management and
analysis.
Data monitoring
The main concern for this type of study is the presence
of suicidal risk in the intervention and control groups.
Suicide risk is increased in depressive disorders, and a
specific question in the depression symptoms score
using BDI-II is dedicated to suicidal ideas. Therefore,
monitoring this specific question is important during
the study. For this reason, the BDI-II questionnaires
will be completed at the clinic and the answers
checked by the clinician while the participants are in
the program. If the suicide question is checked posi-
tive, the patient will be asked to stay in the clinic, and
the patient psychiatric care provider will be informed.
This is a common practice for clinical and research
processes taken place at the mood disorders clinic. The
use of BDI-II is also a common practice, and all clini-
cians are familiar with scoring and checking the suicide
question.
This study does not require a data and safety monitor-
ing board due to the reasons described above in a social/
behavioural research type of study.
Harms
This study is a minimal risk non-pharmaceutical study;
however, there may be risks involved including anxiety
or fatigue when completing the study questionnaires, in-
terviews and attending groups. In addition, participants
allocated to the control group may feel disappointed that
they did not receive the new intervention. The study in-
vestigators interviewing participants and administering
intervention/control conditions are experienced clini-
cians delivering psychiatric care at the clinic; in addition,
all participants will also continue to have usual care. The
study clinicians will be in close contact with participants’
clinical teams. If participants are seen in distress, fatigue
or anxious situations, the clinician will attend to the par-
ticipant needs and remove them from the group/study if
necessary.
Auditing
The study team will meet weekly to discuss the study
progress and review the weekly report of study recruit-
ment, data quality and monitoring of attendance and
any issues raised by the participants or the clinicians.
Research ethics approval
Approval from the Hamilton Integrated Research Ethics
Board (HIREB) has been obtained.
Protocol amendments
Any changes to the study protocol (expected during and
after the completion of the pilot phase) will be reported
to the HIREB prior to implementation. In addition, any
protocol deviations/violations will be reported promptly,
and a note to file will be kept in the study file.
Consent
Informed consent will be obtained during a face-to-face
interview with potential participants by a member of the
research team in a private office within the hospital
premises. Details of the study procedures and time com-
mitment will be explained verbally and reviewed with
the potential participants for any questions. Any ques-
tions arising will be answered accordingly. The informed
consent form will be reviewed page by page with each
potential participant. Participants will be informed that
they can request additional time to consider participa-
tion and take a copy of the consent form to review at
their leisure before making a decision on enrolling in the
study.
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Confidentiality
All study personnel will be trained and monitored regu-
larly in the requirement of participants’ confidentiality
according to hospital and research ethics board regula-
tions and following good clinical practice guidelines. All
research-related procedures including data collection
and storage will be carried out in secure clinical and
research-designated areas within the hospital property.
No information about any participants will be shared
outside the research team without prior consent unless
there are concerns regarding participant health and
safety, and in this instance, these concerns will be com-
municated to the participant and their clinician.
Access to data
Study investigators will have access to the pilot trial
data.
Post trial care
All study participants have access to care at the Mood
Disorders Program during the pilot trial and will con-
tinue to receive usual care at the conclusion of the pilot
trial. The pilot trial procedures do no replace any exist-
ing services that the participants are otherwise receiving.
Dissemination
The Mood Disorders Program website will be used to
introduce the behavioural activation program. In addition,
participants will be informed on the main trial progress
through a newsletter that will be posted on website and
mailed to participants yearly.
The trial results will be shared with healthcare profes-
sionals through grand rounds presentations, scientific
meetings and peer-reviewed publications.
For the public at large, the trial results will be pre-
sented at the annual Mood Disorders Program Tackling
Depression event hosted once per year to disseminate
mood disorder-related topics to health care providers
within the community and the general public.
The trial reporting will follow the CONSORT statement
extension for pragmatic trials [29]. The study protocol fol-
lows the SPIRIT guidelines [43].
Discussion
This study protocol will help to implement the pilot and
ultimately the main trial in a transparent way to assist
in improving the reporting and conduct of non-
pharmaceutical clinical trials. The pilot study will show
if the program of behavioural activation is feasible to be
delivered at the planned frequency and duration of
intervention. The pilot study will also provide insight
into the feasibility of an 18-week follow-up for patients
with major depressive disorder. Provided we demon-
strate that an 18-week follow-up is feasible, we may
consider the additional time needed to establish effect-
iveness among this patient population.
In addition, the feedback from the participants will be
important to design patient-focused interventions that
are likely to be used by participants in the future. We
anticipated challenges during the pilot study to include
the time commitment to the intervention and the face-
to-face visits to the hospital. Concerns regarding the
time, cost (for example parking/transportation) and at-
tendance of the control group as they will be aware that
the group they are allocated to is the control group. If
such challenges were to arise, we will attempt to over-
come these challenges, we will offer public transporta-
tion and parking costs for all participants and we will
offer behavioural activation to the control group once
the pilot trial is completed.
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